Legal entity
court-decisions is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Center for Reproductive Rights, the most common co-covered peer. We currently track 1 Legal story that mention U.S. Court of Appeals for the Fifth Circuit, all published on September 10, 2026.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
court-decisions is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Center for Reproductive Rights, the most common co-covered peer. We currently track 1 Legal story that mention U.S. Court of Appeals for the Fifth Circuit, all published on September 10, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. Court of Appeals for the Fifth Circuit. Shared-story counts are live from our verified record — not editorial picks.
Fifth Circuit hears Louisiana v. FDA
The U.S. Court of Appeals for the Fifth Circuit in New Orleans holds oral arguments in a case that could end telehealth mifepristone access nationwide.
Choices Women's Center launches telehealth
Dr. Richardson begins offering telehealth abortion services at his Tucson clinic, and adoption takes off with 95% of patients choosing telemedicine.
Arizona court clears telehealth abortion
A judge rules in favor of Dr. William Richardson in a lawsuit filed by the Center for Reproductive Rights, removing state restrictions on telehealth mifepristone in Arizona.
FDA makes telehealth mifepristone rule official
The FDA formally codifies the policy allowing mifepristone to be prescribed via telehealth and dispensed by mail.
FDA begins allowing telehealth mifepristone
During the COVID-19 pandemic, the FDA begins allowing the abortion pill mifepristone to be prescribed through telehealth and sent to patients in the mail.
The Fifth Circuit is hearing Louisiana v. FDA, a case that could invalidate the FDA's 2023 telehealth mifepristone rule nationwide. For legal and regulatory professionals, it tests federal agency authority, state standing, and the durability of telehealth abortion access.
U.S. Court of Appeals for the Fifth Circuit is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
